Portal de Periódicos da CAPES

Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer

2022; American Association for Cancer Research; Volume: 82; Issue: 12_Supplement Linguagem: Inglês

10.1158/1538-7445.am2022-3580

1538-7445

Arvind Ravi, Justin F. Gainor, Monica Arniella, Chip Stewart, Sam Freeman, Mark M. Awad, Patrick M. Forde, Valsamo Anagnostou, Brian S. Henick, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamisdhar Velcheti, Ignaty Leshchiner, Jaegil Kim, Subba R. Digumarthy, Mari Mino‐Kenudson, John V. Heymach, Natalie I. Vokes, Andrew Griffin, Biagio Ricciuti, Naiyer A. Rizvi, Roy S. Herbst, Victor E. Velculescu, Julie R. Brahmer, Kurt A. Schalper, Pasi A. Jänne, Jedd D. Wolchok, Alice T. Shaw, Nir Hacohen, Gad Getz, Matthew D. Hellmann,

Cancer Immunotherapy and Biomarkers

Abstract The introduction of checkpoint blockade therapy, specifically anti-PD-1/PD-L1 agents, has transformed the treatment landscape of advanced Non-Small Cell Lung Cancer (NSCLC). While our understanding of the biology underlying immunotherapy in NSCLC is still incomplete, studies to date have established central roles for Tumor Mutation Burden (TMB) and PD-L1 Tumor Proportion Score (PDL1-TPS). In order to expand our understanding of the molecular features underlying response in NSCLC, we describe here the first joint analysis of the Stand Up 2 Cancer-Mark Foundation (SU2C-MARK) Cohort, a collection of 393 patients with whole exome and/or RNA sequencing along with matched checkpoint blockade response annotation. We identify a number of significant associations between molecular features and response, including: 1) favorable and unfavorable genomic subgroups; 2) distinct immune infiltration signatures associated with wound healing (unfavorable) and immune activated (favorable) microenvironments; and 3) a novel de-differentiated tumor-intrinsic subtype characterized by high TMB, immune activation, and enhanced response rate. Taken together, results from this cohort extend our understanding of NSCLC-specific predictors, providing a rich set of molecular and immunologic hypotheses with which to further our understanding of the biology of checkpoint blockade in NSCLC. Citation Format: Arvind Ravi, Justin Gainor, Monica Arniella, Chip Stewart, Sam Freeman, Mark M. Awad, Patrick Forde, Valsamo Anagnostou, Brian Henick, Jonathan W. Riess, Don Gibbons, Nathan Pennell, Vamisdhar Velcheti, Ignaty Leshchiner, Jaegil Kim, Subba Digumarthy, Mari Mino-Kenudson, John Heymach, Natalie Vokes, Andrew Griffin, Biagio Ricciuti, Naiyer Rizvi, Roy Herbst, Victor Velculescu, Julie Brahmer, Kurt Schalper, Pasi Janne, Jedd Wolchok, Alice Shaw, Nir Hacohen, Gad Getz, Matthew D. Hellmann. Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3580.